Literature DB >> 9835534

Efficacies of cefepime, ceftazidime, and imipenem alone or in combination with amikacin in rats with experimental pneumonia due to ceftazidime-susceptible or -resistant Enterobacter cloacae strains.

O Mimoz1, A Jacolot, S Leotard, N Hidri, K Samii, P Nordmann, O Petitjean.   

Abstract

The antibacterial activities of human regimens of cefepime, ceftazidime, and imipenem alone or in combination with amikacin against an isogenic pair of Enterobacter cloacae strains (wild type and its corresponding derepressed cephalosporinase mutant) were compared by using our nonlethal model of pneumonia with 180 immunocompetent rats. Compared with untreated animals, all beta-lactam-treated rats, except those inoculated with the mutant isolate and receiving ceftazidime, had significantly lower bacterial counts in their lungs 60 h after the onset of therapy. Although the combination of a beta-lactam and amikacin was more bactericidal than each corresponding antimicrobial agent alone, true synergy was noted only with cefepime and imipenem against the constitutive derepressed strain.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9835534      PMCID: PMC106042     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

Review 1.  High-performance liquid chromatography of antibiotics.

Authors:  F Jehl; C Gallion; H Monteil
Journal:  J Chromatogr       Date:  1990-10-12

2.  Treatment of a meningitis due to an Enterobacter aerogenes producing a derepressed cephalosporinase and a Klebsiella pneumoniae producing an extended-spectrum beta-lactamase.

Authors:  C de Champs; D Guelon; D Joyon; D Sirot; M Chanal; J Sirot
Journal:  Infection       Date:  1991 May-Jun       Impact factor: 3.553

3.  Activity of cefepime, ceftazidime, and ceftizoxime against mutants of Enterobacteriaceae and Pseudomonas aeruginosa derepressed for class I beta-lactamase.

Authors:  C C Knapp; J A Washington
Journal:  J Antimicrob Chemother       Date:  1989-12       Impact factor: 5.790

4.  Cefepime and amikacin synergy in vitro and in vivo against a ceftazidime-resistant strain of Enterobacter cloacae.

Authors:  O Mimoz; A Jacolot; C Padoin; M Tod; K Samii; O Petitjean
Journal:  J Antimicrob Chemother       Date:  1998-03       Impact factor: 5.790

5.  Type I beta-lactamases of gram-negative bacteria: interactions with beta-lactam antibiotics.

Authors:  C C Sanders; W E Sanders
Journal:  J Infect Dis       Date:  1986-11       Impact factor: 5.226

6.  High-pressure liquid chromatographic analysis of BMY-28142 in plasma and urine.

Authors:  R H Barbhaiya; S T Forgue; W C Shyu; E A Papp; K A Pittman
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

7.  Reevaluation of the factors involved in the efficacy of new beta-lactams against Enterobacter cloacae.

Authors:  F Bellido; J C Pechère; R E Hancock
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

8.  Determination of imipenem (N-formimidoyl thienamycin) in human plasma and urine by high-performance liquid chromatography, comparison with microbiological methodology and stability.

Authors:  D A Gravallese; D G Musson; L T Pauliukonis; W F Bayne
Journal:  J Chromatogr       Date:  1984-09-14

9.  Activity of cefepime (BMY-28142) and cefpirome (HR 810) against gram-negative bacilli resistant to cefotaxime or ceftazidime.

Authors:  R N Jones; P C Fuchs
Journal:  J Antimicrob Chemother       Date:  1989-01       Impact factor: 5.790

10.  Affinity of cephalosporins for beta-lactamases as a factor in antibacterial efficacy.

Authors:  D J Phelps; D D Carlton; C A Farrell; R E Kessler
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

View more
  5 in total

1.  An SHV-derived extended-spectrum beta-lactamase in Pseudomonas aeruginosa.

Authors:  T Naas; L Philippon; L Poirel; E Ronco; P Nordmann
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Pharmacodynamics of cefepime alone and in combination with various antimicrobials against methicillin-resistant Staphylococcus aureus in an in vitro pharmacodynamic infection model.

Authors:  Vanthida Huang; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

3.  Effect of porins and plasmid-mediated AmpC beta-lactamases on the efficacy of beta-lactams in rat pneumonia caused by Klebsiella pneumoniae.

Authors:  Emma Padilla; Diana Alonso; Antonio Doménech-Sánchez; Cristina Gomez; José Luis Pérez; Sebastián Albertí; Nuria Borrell
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

4.  Efficacies of imipenem, meropenem, cefepime, and ceftazidime in rats with experimental pneumonia due to a carbapenem-hydrolyzing beta-lactamase-producing strain of Enterobacter cloacae.

Authors:  O Mimoz; S Leotard; A Jacolot; C Padoin; K Louchahi; O Petitjean; P Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

5.  In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model.

Authors:  George P Allen; Raymond Cha; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.